







**Figure 1.** Photograph of a 36-years-old male in enface (a) and profile (b) views. The swelling is evident at the bridge of the nose extending to the left infraorbital region. There is pink coloration over the swelling.



**Figure 2.** Ultrasound examination. (a) Grayscale image shows slightly heterogenous mass with few necrotic areas. (b) The lesion shows increased vascularity within the mass.



**Figure 3.** CECT of the neck and facial region. (a) Axial section shows the enhancing mass in the left sino-nasal region (horizontal arrow) which is pressing upon the adjoining structures. (b) Sagittal section reveals the same mass showing extension in the base of the skull (vertical arrow) and posteriorly up to the sphenoid sinus. There is a total involvement of ethmoid and sphenoid regions. (c) Well-margined enhancing mass with visible vessels (star). The mass is causing displacement of the left orbit laterally.

(Figure 3). The bone window revealed expansion of the tumor causing thinning out of the bone with partial destruction (Figure 4).

Magnetic resonance imaging (MRI) was performed to know more about the characterization of the mass. The mass was well-defined and of mixed intensity (Figure 5).




**Figure 4.** Axial section CT in the bone window at the tumor level. This shows the outstretched eaten up bone with the tumor expansion.

The patient underwent complete excision of the mass under general anesthesia. The histopathological specimen revealed lobules of monomorphic tumor cells with occasional mitosis. The cells are immunopositive for MIC-2, while negative for synaptophysin, chromogranin, pancytokeratin; CD56 and myogenin. Findings were consistent with Ewing's sarcoma/peripheral PNET. This was followed by six cycles of Vincristine-Ifosfamide-Doxorubicin-Etoposide chemotherapy. The patient had an uneventful recovery and is on yearly follow-up.

### Discussion

Malignant tumors with monomorphic population of undifferentiated cells with scanty cytoplasm and small nuclei form a heterogeneous group of small round blue cell neoplasms. Ewing sino-nasal is a high-grade round-cell tumor of childhood and adolescent with a predilection for male [2]. This has got higher malignant potential with both skeletal and extraskelatal manifestations. This gives the clinical appearance of osteomyelitis [3]. The manifestations in the head and neck regions are slightly rare but our present case had both skeletal as well as soft tissue involvement. The long bones are frequently involved. Soft tissue of lower extremities, paravertebral tissues, retroperitoneum, and chest wall are frequently involved. Maxilla and mandible are frequently involved



**Figure 5.** MRI images at the level of the bridge of the nose. (a) Axial T2WI shows mixed intensity mass with a well defined outline (vertical arrow). The mass is displacing the left eye globe rather evading it. (b) Coronal T2WI shows the supero-inferior extent of the mass (horizontal arrow).

as compared to sino-nasal region [4]. The extension of the tumor was assessed on the clinical features and computed tomography (CT). CECT is also helpful in evaluating for distant metastasis. Superficial tumors can also be assessed by USG and color flow imaging as in our present case. MRI is also helpful in some cases to know about the tissue characterization and assess the bleeding within the mass. Bone marrow biopsy and bone scintigraphy are also helpful in hidden metastatic foci. The approach is for the earliest accurate diagnosis and management. But unfortunately, the exact diagnosis made on H&E light microscope picture is also not the answer. This has to be coupled with IHC. The appearance is white in color with polypoidal and lobulated outline. It is mainly less than 10 cm in size. Histologically, this is in the form of densely packed small round cells in lobular form. There are intracellular deposits of glycogen which makes the cytoplasm as pale and ill-defined [5]. The differential diagnosis includes all small round blue cell pathologies. Glycogen in tumor cells can be highlighted with periodic acid-Schiff. In one study twenty-five percent of the patients had skeletal or visceral metastasis when diagnosed [6]. The management requires a long list depending upon the type of tumor. This extends from surgical excision followed by chemotherapy or radio-chemotherapy if the tumor is non-operable [7,8]. The age of the patient, stage, anatomic location, and size of the tumor had been taken as the prognostic factors as per the study conducted by Yeshvanth et al. The 5 years survival was 22% with metastasis and 55% without it [9].

### Conclusion

ES of the sino-nasal region is rare with a wide spectrum and requires multi-modality diagnosis by cross-sectional imaging. This is required to be confirmed by histopathology and IHC. It is important to know about the extent of the tumor and to know if this had metastasized to some

other organs. The management solely depends upon the type of neoplasm.

### Acknowledgment

We are thankful to Mr. Prahlad and Kasif for providing us the CT and MRI images and helping in conducting the investigations.

### Ethical Approval

Not required

### List of Abbreviations

CECT	Contrast-enhanced computerized tomography
CT	Computed tomography
ES	Ewing sarcoma
PNET	Primitive neuroectodermal tumors

### Consent for publication

Written consent of the patient was taken.

### Author details

Shweta Sharma<sup>1</sup>, Shantnu Singh Chauhan<sup>2</sup>, Mir Rizwan Aziz<sup>2</sup>, Nalin Chugh<sup>2</sup>, Bharat Bhushan Sharma<sup>2</sup>, Nitish Virmani<sup>3</sup>

1. ENT Speciality registrar, Warwick Hospital Flat No 9.Lakin House, Warwick CV345BW UK
2. Department of Radiodiagnosis, SGT Medical College, Gurgaon, India
3. Faculty of Allied Health Sciences, SGT University, Gurgaon, India

### References

1. Bridge JA, Bowen JM, Smith RB. The small round cell tumors of the sinonasal area. *Head Neck Pathol.* 2010;4(1):84–93. <https://doi.org/10.1007/s12105-009-0158-6>
2. Kleihues P, Sobin LH. World Health Organization classification of tumors. *Cancer.* 2000;88(12):2887. [https://doi.org/10.1002/1097-0142\(20000615\)88:12<2887::AID-CN-CR32>3.0.CO;2-F](https://doi.org/10.1002/1097-0142(20000615)88:12<2887::AID-CN-CR32>3.0.CO;2-F)
3. Cotterill SJ, Ahrens S, Paulussen M, Jurgens HF, Voute PA, Gadner H, et al. Prognostic factors in Ewing's tumor of bone: analysis of 975 patients from the European Intergroup Cooperative Ewing's Sarcoma Study Group. *J Clin Oncol.* 2000;18(17):3108–14. <https://doi.org/10.1200/JCO.2000.18.17.3108>
4. Patil AM, Yendigeri SM, Sajjanar BB, Kubadi SS. Ewing sarcoma/PNET of sinonasal region: a rare case report. *Sci J.* 2013;2(2):251–5.
5. Desai SS, Jambhekar N. A pathology of ewing's sarcoma/PNET current option and emerging concepts. *Indian J Orthop.* 2010;44(4):363–7. <https://doi.org/10.4103/0019-5413.69304>
6. Thompson LDR. Ewing sarcoma and primitive neuroectodermal tumor. *ENT J.* 2007;86(2):79.
7. Granowetter L, Womer R, Devidas M, Krailo M, Wang C, Bernstein M, et al. Dose-intensified compared with standard chemotherapy for non metastatic Ewing sarcoma family of tumors :a Children's Oncology Group Study. *J Clin Oncol.* 2009;27(15):2536–41. <https://doi.org/10.1200/JCO.2008.19.1478>
8. Grier HE, Krailo MD, Tarbell NJ, Link MP, Fryer CJH, Pritchard DJ, et al. Addition of ifosamide and Etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuro-ectodermal tumor of bone. *N Engl J Med.* 2003;348(8):694–701. <https://doi.org/10.1056/NEJMoa020890>
9. Yeshvanth SK, Ninan K, Bhandary SK, Lakshinarayana KP, Shetty JK, Makannavar JH. Rare case of extraskeletal Ewings sarcoma of the sinonasal tract. *J Cancer Res Ther.* 2012;8(1):142. <https://doi.org/10.4103/0973-1482.95197>

### Summary of the case

<b>Patient</b>	1	36-years-old male
<b>Final diagnosis</b>	2	Ewing's sino-nasal tumor
<b>Symptoms</b>	3	Swelling over the nose and epistaxis
<b>Medications (Generic)</b>	4	Symptomatic with post-operative chemotherapy
<b>Clinical procedure</b>	5	Surgical excision
<b>Specialty</b>	6	Radio-diagnosis